RecruitingNCT06410976
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL
Sponsor
QED Therapeutics, a BridgeBio company
Enrollment
150 participants
Start Date
Jun 5, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Eligibility
Min Age: 30 MonthsMax Age: 16 Years
Inclusion Criteria5
- Signed informed consent.
- Aged 2.5 to <17 years at study entry.
- Diagnosis of HCH documented clinically by the presence of disproportionate short stature and confirmed with a molecular test.
- Participants are ambulatory and able to stand without assistance.
- Study participants and parent(s), guardian(s), or caregiver(s) are willing and able to comply with study visits and study procedures.
Exclusion Criteria13
- Have ACH or short stature condition other than HCH.
- In females, having had their menarche. Annualized height growth velocity ≤1.5 cm/year over a period ≥6 months prior to screening.
- Having a clinically significant disease or condition that in view of the investigator or Sponsor will interfere with the evaluation of growth, with study participation or not be in the best interest of the participant.
- Clinically significant abnormality in any laboratory test result at screening
- Current evidence of corneal or retinal disorders.
- Have used any other investigational or approved product or medical device for the treatment of HCH or short stature for ≥ 30 days or with the last dose <6 months before screening.
- Have had regular long-term treatment (>1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable).
- Previous limb-lengthening surgery or guided growth surgery with plates still in place or removed within the 6 months prior to screening.
- Having had a fracture of the long bones or spine within 12 months of screening.
- History and/or current evidence of extensive ectopic tissue calcification.
- History of malignancy.
- Concurrent circumstance, disease, or condition that, in the view of the investigator and/or sponsor, would interfere with study participation, and/or would place the participant at high risk for poor compliance with study activities or for not completing the study.
- Current participation in any other ongoing clinical study with another sponsor.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06410976
Related Trials
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT0712626226 locations
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
NCT073889661 location
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT0621294743 locations
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
NCT053280501 location